Statins for the primary prevention of cardiovascular disease.
暂无分享,去创建一个
Mark D. Huffman | M. Huffman | S. Ebrahim | G. Davey Smith | M. Burke | F. Taylor | Kirsten J. Ward | T. Moore | A. F. Macedo
[1] Jennifer G. Robinson,et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[2] N. Jewell,et al. Should people at low risk of cardiovascular disease take a statin? , 2013, BMJ.
[3] J. McMurray,et al. Effect of rosuvastatin on fatigue in patients with heart failure. , 2013, Journal of the American College of Cardiology.
[4] D. Panagiotakos,et al. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study , 2013, The Lancet.
[5] Joel E Dimsdale,et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. , 2012, Archives of internal medicine.
[6] J. Casas,et al. Statins for all by the age of 50 years? , 2012, The Lancet.
[7] W. Kostis,et al. Statin Therapy and the Risk of Intracerebral Hemorrhage: A Meta-Analysis of 31 Randomized Controlled Trials , 2012, Stroke.
[8] L. Smeeth,et al. Improving vascular health: are pills the answer? , 2012, BMJ : British Medical Journal.
[9] Avis J. Thomas,et al. Lifetime risks of cardiovascular disease. , 2012, The New England journal of medicine.
[10] John Simes,et al. Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy , 2012, PloS one.
[11] R. Collins,et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial , 2011 .
[12] A. A. Teixeira,et al. Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients , 2011, Journal of Human Hypertension.
[13] E. Colman,et al. Weighing the benefits of high-dose simvastatin against the risk of myopathy. , 2011, The New England journal of medicine.
[14] L. Goldman,et al. Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era , 2011, Circulation.
[15] P. Ridker,et al. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. , 2011, American heart journal.
[16] M. Taskinen,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.
[17] Paul Welsh,et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.
[18] J. Borén,et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.
[19] P. Barter,et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. , 2011, Journal of the American College of Cardiology.
[20] M. Caulfield,et al. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm , 2011, Journal of hypertension.
[21] R. Collins,et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. , 2011 .
[22] G. Guyatt,et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. , 2011, QJM : monthly journal of the Association of Physicians.
[23] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[24] B. Cheung,et al. Is intensive LDL-cholesterol lowering beneficial and safe? , 2010, The Lancet.
[25] P. Ridker,et al. The JUPITER Trial: responding to the critics. , 2010, The American journal of cardiology.
[26] Paul M Ridker,et al. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities , 2010, European heart journal.
[27] J. Cowan,et al. Simvastatin in the treatment of asthma: lack of steroid-sparing effect , 2010, Thorax.
[28] J. Hsia,et al. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial , 2010, Journal of medical economics.
[29] Y. Ohashi,et al. Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese. , 2010, Journal of atherosclerosis and thrombosis.
[30] D. O'leary,et al. C‐reactive protein lowering with rosuvastatin in the METEOR study , 2010, Journal of internal medicine.
[31] P. Libby,et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial , 2010, The Lancet.
[32] P. Libby,et al. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). , 2010, The American journal of cardiology.
[33] J Wouter Jukema,et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. , 2010, Archives of internal medicine.
[34] J. Zamorano,et al. TREATMENT STRATEGIES FOR CARDIOVASCULAR RISK FACTOR MANAGEMENT IN PATIENTS WITH HYPERTENSION AND ADDITIONAL RISK FACTORS - EXPERIENCES FROM THE USUAL CARE ARM OF THE CRUCIAL TRIAL: PP.16.90 , 2010 .
[35] M. Sahraian,et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial , 2010, Multiple sclerosis.
[36] Carol Coupland,et al. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database , 2010, BMJ : British Medical Journal.
[37] Robert J. Glynn,et al. Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial , 2010, Annals of Internal Medicine.
[38] S. Wattanasirichaigoon,et al. Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. , 2010, Bone.
[39] I. Marschner,et al. Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study , 2010, BMC medical research methodology.
[40] G. Parati,et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial , 2010, British medical journal.
[41] P. Ridker,et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. , 2010, Journal of the American College of Cardiology.
[42] P. Sullivan,et al. STATIN THERAPY IS COST-EFFECTIVE FOR VASCULAR EVENT PREVENTION IN ADULTS WITH ELEVATED C-REACTIVE PROTEIN: IMPLICATIONS OF JUPITER , 2010 .
[43] K. Teo,et al. INTERACTION BETWEEN ROSUVASTATIN AND HIGH SENSITIVITY C-REACTIVE PROTEIN ON PROGRESSION OF AORTIC STENOSIS , 2010 .
[44] Yasuo Ohashi,et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.
[45] H. Shimomura,et al. Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[46] K. Teo,et al. Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.
[47] P. Ridker,et al. Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) , 2010, Circulation.
[48] E. Amsterdam,et al. Another look at the results of the JUPITER trial. , 2009, The American journal of cardiology.
[49] G. Hitman,et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[50] Robert Dufour,et al. Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .
[51] Y. Matsuzawa,et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). , 2009, Atherosclerosis.
[52] A. Gotto,et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). , 2009, The American journal of cardiology.
[53] Y. Ohashi,et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: Analysis of data from the MEGA Study, a large randomized controlled trial , 2009, Journal of the Neurological Sciences.
[54] Francisco A H Fonseca,et al. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study , 2009, Expert review of cardiovascular therapy.
[55] S. Grundy,et al. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. , 2009, The American journal of cardiology.
[56] D. Parra,et al. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial , 2009, The Lancet.
[57] J Shepherd,et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.
[58] W. Sluiter,et al. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein , 2009, Expert opinion on therapeutic targets.
[59] D. Grobbee,et al. Abstract: P952 C-REACTIVE PROTEIN LOWERING WITH ROSUVASTATIN IN THE METEOR STUDY , 2009 .
[60] D. Grobbee,et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study , 2009, Journal of internal medicine.
[61] J. Crouse. Abstract: 88 EFFECTS OF STATIN THERAPY ON THE CAROTID ARTERY , 2009 .
[62] R. Kones. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease , 2009, Therapeutic advances in cardiovascular disease.
[63] V. Mok,et al. Statins for Asymptomatic Middle Cerebral Artery Stenosis: The Regression of Cerebral Artery Stenosis Study , 2009, Cerebrovascular Diseases.
[64] J. O’Keefe,et al. The Gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) , 2009, Postgraduate medicine.
[65] P. Ridker. The JUPITER Trial: Results, Controversies, and Implications for Prevention , 2009, Circulation. Cardiovascular quality and outcomes.
[66] P. Libby,et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. , 2009, The New England journal of medicine.
[67] Børge G Nordestgaard,et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.
[68] J. Almendral,et al. Reduction of Heat Shock Protein Antibody Levels by Statin Therapy , 2009, Lipids.
[69] R. Collins,et al. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people , 2009, BMC clinical pharmacology.
[70] S. Nissen. The Jupiter trial: Key findings, controversies, and implications , 2009, Current cardiology reports.
[71] R. Collins,et al. Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels , 2009, Circulation. Cardiovascular quality and outcomes.
[72] Y. Ohashi,et al. Pravastatin for Cardiovascular Event Primary Prevention in Patients With Mild-to-Moderate Hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study , 2009, Hypertension.
[73] P. Ridker,et al. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. , 2009, Clinical chemistry.
[74] G. Hitman,et al. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS) , 2009, Diabetologia.
[75] Andres F Zuluaga,et al. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics , 2009, BMC clinical pharmacology.
[76] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[77] S. D. de Ferranti,et al. Storm over statins--the controversy surrounding pharmacologic treatment of children. , 2008, The New England journal of medicine.
[78] G. Hitman,et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS) , 2008, Diabetes & vascular disease research.
[79] R. Blumenthal,et al. Placing COURAGE in context: review of the recent literature on managing stable coronary artery disease. , 2008, Mayo Clinic proceedings.
[80] H. Müderrisoğlu,et al. Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients. , 2008, Pharmacological research.
[81] J. Fleg,et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. , 2008, JAMA.
[82] Jonathan A C Sterne,et al. Investigating and Dealing with Publication and Other Biases , 2008 .
[83] Stephen S. Lim,et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs , 2007, The Lancet.
[84] D. Kiel,et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. , 2007, The Journal of clinical endocrinology and metabolism.
[85] R. Collins,et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.
[86] L. E. Ortega-Pierres,et al. Rosuvastatina y metformina reducen la inflamación y el estrés oxidativo en pacientes con hipertensión y dislipemia , 2007 .
[87] J. Fuller,et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS) , 2007, Diabetic medicine : a journal of the British Diabetic Association.
[88] P. Libby,et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. , 2007, The American journal of cardiology.
[89] J. Armitage,et al. The safety of statins in clinical practice , 2007, The Lancet.
[90] P. Macfarlane,et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. , 2007, The New England journal of medicine.
[91] Jing Wu,et al. [Effect of atorvastatin on carotid intima-medial of thickness of primary hypertension patients of Han nationality in China]. , 2007, Zhonghua yi xue za zhi.
[92] J. Shepherd. Cholesterol lowering with statins: how WOSCOPS confounded the skeptics. , 2007, Atherosclerosis. Supplements.
[93] H. Nakamura. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. , 2007, Atherosclerosis. Supplements.
[94] B. Mazurek,et al. Effect of Atorvastatin on Progression of Sensorineural Hearing Loss and Tinnitus in the Elderly: Results of a Prospective, Randomized, Double-Blind Clinical Trial , 2007, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
[95] M. Janghorbani,et al. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus , 2007, Acta Diabetologica.
[96] S. Ward,et al. A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.
[97] M. Lauer. Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. , 2007, JAMA.
[98] Diederick E Grobbee,et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. , 2007, JAMA.
[99] D. Grobbee,et al. Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: baseline data from the METEOR study* , 2007, Current medical research and opinion.
[100] Y. Matsuzawa,et al. Effects of Hypertension and Type 2 Diabetes Mellitus on the Risk of Total Cardiovascular Events in Japanese Patients with Hypercholesterolemia: Implications from the Japan Lipid Intervention Trial (J-LIT) , 2007, Hypertension Research.
[101] J. Abramson,et al. Are lipid-lowering guidelines evidence-based? , 2007, The Lancet.
[102] S. Anderssen,et al. Effect of lifestyle and/or statin treatment on soluble markers of atherosclerosis in hypertensives , 2007, Scandinavian cardiovascular journal : SCJ.
[103] T. Imaizumi,et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes , 2006, Clinical and Experimental Medicine.
[104] M Alan Brookhart,et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.
[105] G. Hitman,et al. Analysis of Efficacy and Safety in Patients Aged 65–75 Years at Randomization , 2006, Diabetes Care.
[106] Yasuo Ohashi,et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.
[107] P. Toth,et al. The CARDS trial: Diabetic patients dealt a winning hand , 2006, Current atherosclerosis reports.
[108] A. Smit,et al. Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. , 2006, Atherosclerosis.
[109] S. Agewall,et al. Atorvastatin normalizes endothelial function in healthy smokers. , 2006, Clinical science.
[110] S. Pocock,et al. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.
[111] D. Lawlor,et al. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study , 2006, BMJ : British Medical Journal.
[112] Peter Tanuseputro,et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study , 2006, BMJ : British Medical Journal.
[113] Harlan M Krumholz,et al. Withdrawn: P68 , 2006 .
[114] E. L. D. Sá,et al. Análisis coste-efectividad del uso de atorvastatina en pacientes diabéticos de tipo 2: modelo farmacoeconómico del estudio CARDS , 2006 .
[115] S. Achenbach,et al. Effect of Intensive Versus Standard Lipid-Lowering Treatment With Atorvastatin on the Progression of Calcified Coronary Atherosclerosis Over 12 Months: A Multicenter, Randomized, Double-Blind Trial , 2006, Circulation.
[116] C Michael White,et al. Statins and Cancer Risk: A Meta-analysis , 2007 .
[117] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[118] M Egger,et al. The causes and effects of socio-demographic exclusions from clinical trials. , 2005, Health technology assessment.
[119] J. Jukema,et al. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. , 2005, Diabetes care.
[120] H. Putter,et al. No effect of statin therapy on silent myocardial ischemia in patients with type 2 diabetes without manifest cardiovascular disease. , 2005, Diabetes care.
[121] S. Anderssen,et al. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. , 2005, Atherosclerosis.
[122] G. Mancia,et al. Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of PHYLLIS—A Randomized Double-Blind Trial , 2004, Stroke.
[123] H. Putter,et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. , 2004, Diabetes care.
[124] Hans L. Hillege,et al. Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.
[125] H. Hillege,et al. Framingham score and microalbuminuria: combined future targets for primary prevention? , 2004, Kidney international. Supplement.
[126] M. Briel,et al. Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials , 2004 .
[127] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[128] T. Wilt,et al. Effectiveness of statin therapy in adults with coronary heart disease. , 2004, Archives of internal medicine.
[129] R. Paoletti,et al. Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions , 2004, Circulation.
[130] I. Holme,et al. Fluvastatin Prevents Cardiac Death and Myocardial Infarction in Renal Transplant Recipients: Post‐Hoc Subgroup Analyses of the ALERT Study , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[131] B. Cheung,et al. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. , 2004, British journal of clinical pharmacology.
[132] R. Califf,et al. Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 3: diagnosis and treatment of acute cardiac ischemia: gender issues. , 2004, Circulation.
[133] T. Walley,et al. Variations and increase in use of statins across Europe: data from administrative databases , 2004, BMJ : British Medical Journal.
[134] S. Kjeldsen,et al. [Statin therapy for hypertensive patients]. , 2004, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[135] J. Shepherd. Preventing the next event in the elderly: the PROSPER perspective. , 2003, Atherosclerosis. Supplements.
[136] A. Mrhar,et al. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. , 2003, International journal of clinical pharmacology and therapeutics.
[137] P. Ridker. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. , 2003, Circulation.
[138] D. Chinn,et al. Taking simvastatin in the morning compared with in the evening: randomised controlled trial , 2003, BMJ : British Medical Journal.
[139] Mark A. Creager,et al. Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease , 2003, Circulation.
[140] O. Wolkowitz,et al. Behavioral implications of lowering cholesterol levels: a double-blind pilot study. , 2003, Psychosomatics.
[141] Christian Gluud,et al. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? , 2003, JAMA.
[142] Prof. Dr. W. Kübler,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesteroal concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOL-LLA): a multicentre randomised controlled trial , 2003, Zeitschrift für Kardiologie.
[143] A. Wierzbicki,et al. The lipid and non-lipid effects of statins. , 2003, Pharmacology & therapeutics.
[144] N J Wald,et al. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.
[145] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[146] R. Fogari,et al. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. , 2003, Clinical therapeutics.
[147] L. Rodríguez-Mañas,et al. More on PROSPER , 2003, The Lancet.
[148] M. Egger,et al. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001 , 2003, Heart.
[149] L. Sharma,et al. Statin Use and Leg Functioning in Patients With and Without Lower-Extremity Peripheral Arterial Disease , 2003, Circulation.
[150] C. Napoli,et al. Statin effects beyond lipid lowering--are they clinically relevant? , 2003, European heart journal.
[151] A. Branchi,et al. The PROSPER trial , 2003, The Lancet.
[152] J. Austoker,et al. Breast self examination , 2003, BMJ : British Medical Journal.
[153] Barry R. Davis,et al. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.
[154] J. Avorn,et al. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial. , 2002, Controlled clinical trials.
[155] André Scheen,et al. L'étude clinique du mois : L'étude PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) , 2002 .
[156] R. Collins,et al. High-risk elderly patients PROSPER from cholesterol-lowering therapy , 2002, The Lancet.
[157] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[158] Majid Ezzati,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[159] P. Macfarlane,et al. Testing cognitive function in elderly populations: the PROSPER study , 2002, Journal of neurology, neurosurgery, and psychiatry.
[160] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[161] H. Mabuchi,et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. , 2002, Atherosclerosis.
[162] R. Kronmal,et al. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. , 2002, Archives of internal medicine.
[163] M I Mackness,et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[164] S. Kashiwagi,et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). , 2002, Journal of the American College of Cardiology.
[165] S. Yusuf,et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.
[166] I. U. Haq,et al. Statins for primary prevention: at what coronary risk is safety assured? , 2001, British journal of clinical pharmacology.
[167] Y. Ohashi,et al. A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. , 2001, Clinica chimica acta; international journal of clinical chemistry.
[168] Paul M. Ridker,et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.
[169] R. Collins,et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial , 2001, Journal of hypertension.
[170] G. New,et al. Effect Of Anti‐Oxidant Treatment And Cholesterol Lowering On Resting Arterial Tone, Metabolic Vasodilation And Endothelial Function In The Human Forearm: A Randomized, Placebo‐Controlled Study , 2001, Clinical and experimental pharmacology & physiology.
[171] G. Berglund,et al. Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) , 2001, Circulation.
[172] G. Blauw,et al. Dementia and statins , 2001, The Lancet.
[173] S. Manuck,et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials , 2001, BMJ : British Medical Journal.
[174] G. de Simone,et al. Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia , 2000, Diabetes, obesity & metabolism.
[175] C. Mulrow,et al. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials , 2000, BMJ : British Medical Journal.
[176] S. Nozawa,et al. Usefulness of HMG-CoA Reductase Inhibitor in Japanese Hyperlipidemic Women within Seven Years of Menopause , 2000, Hormone Research in Paediatrics.
[177] T. Lee,et al. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. , 2000, The American journal of cardiology.
[178] R. Pandey,et al. Simvastatin retards progression of diabetic retinopathy in hyperlipidemic patients: A double blind randomised control trial , 2000 .
[179] G. Gallus,et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. , 2000, Atherosclerosis.
[180] J. Sasaki,et al. Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with hypercholesterolemia: The Kyushu Lipid Intervention Study (KLIS) , 2000 .
[181] H. Nakamura. The design and background characteristics of the study on the primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. (Japanese Mega Study) , 2000 .
[182] L. Marsh,et al. Treatment of early Parkinson's disease , 2000, BMJ : British Medical Journal.
[183] F. Vrtovsnik,et al. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[184] K. Matthews,et al. Effects of lovastatin on cognitive function and psychological well-being. , 2000, The American journal of medicine.
[185] J. Larosa,et al. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.
[186] P. Macfarlane,et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.
[187] D. Waters,et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. , 1999, The New England journal of medicine.
[188] C. Wanner,et al. Simvastatin in nephrotic syndrome , 1999 .
[189] P. Meraj,et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. , 1999, Journal of the American College of Cardiology.
[190] D A Katerndahl,et al. Variability in meta-analytic results concerning the value of cholesterol reduction in coronary heart disease: a meta-meta-analysis. , 1999, American journal of epidemiology.
[191] Rila,et al. Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle‐aged men free from cardiovascular disease , 1998, Journal of internal medicine.
[192] J. Shepherd,et al. Prevention of heart disease: is LDL reduction the outcome of choice? No, there is more. , 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[193] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[194] M. Eriksson,et al. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid‐lowering in primary care , 1998 .
[195] P. Macfarlane,et al. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.
[196] W. Sheu,et al. S90 Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia , 1998 .
[197] D. Hunninghake,et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.
[198] T. Meade,et al. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk , 1998, The Lancet.
[199] J. McMurray,et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin , 1997, BMJ.
[200] D. Jacobs,et al. Serum total cholesterol and risk of hospitalization, and death from respiratory disease. , 1997, International journal of epidemiology.
[201] J. Flory,et al. Effects of lovastatin on the immune system. , 1997, The American journal of cardiology.
[202] P. Macfarlane,et al. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. , 1997, European heart journal.
[203] D. Jacobs,et al. Reduced cholesterol is associated with recent minor illness: the CARDIA Study. Coronary Artery Risk Development in Young Adults. , 1997, American journal of epidemiology.
[204] H. Komori,et al. 2.P.53 Effects of long-term (for 5 years) treatment using pravastatin sodium on hyperlipidemia in diabetics , 1997 .
[205] H. Komori,et al. 2.P.51 Escape phenomenon during the long-term administration of pravastatin for phyperlipideia associated with diabetes , 1997 .
[206] J. Mckenney,et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. , 1997, The American journal of cardiology.
[207] R. Westendorp,et al. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.
[208] S. Cobbe. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. , 1997, The American journal of cardiology.
[209] E. Stein,et al. Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia , 1997, Journal of cardiovascular pharmacology and therapeutics.
[210] N. Santanello,et al. Effect of Pharmacologic Lipid Lowering on Health‐Related Quality of Life in Older Persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study , 1997, Journal of the American Geriatrics Society.
[211] G. Gallus,et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. , 1996, The American journal of medicine.
[212] P. Macfarlane,et al. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .
[213] B. Tomlinson,et al. Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects. , 1996, Hypertension.
[214] R. Collins,et al. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration , 1996, BMJ.
[215] B. Scherstén,et al. Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study , 1996, Journal of internal medicine.
[216] L. Cattin,et al. Efficacy and safety of simvastatin in current clinical practice: the italian family physician simvastatin study , 1996 .
[217] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[218] J. Salonen,et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.
[219] H. Buchwald,et al. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). , 1995, Journal of the American College of Cardiology.
[220] G. Gallus,et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study , 1995, The International Journal of Cardiac Imaging.
[221] A. Branchi,et al. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients. , 1995, International journal of clinical pharmacology and therapeutics.
[222] B. Scherstén,et al. The impact of health care advice given in primary care on cardiovascular risk , 1995 .
[223] A. Yeung,et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.
[224] C. Shear,et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. , 1994, The American journal of cardiology.
[225] C. Furberg,et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.
[226] M. Sugimachi,et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.
[227] P. Théroux,et al. Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients , 1994, Annals of Internal Medicine.
[228] D. Gordon,et al. Cholesterol Lowering in the Elderly: Results of the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study , 1994 .
[229] Z. Varghese,et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. , 1993, Kidney international.
[230] P. Erne,et al. [Pravastatin in the treatment of primary hypercholesterolemia: a Swiss multicenter study]. , 1993, Schweizerische medizinische Wochenschrift.
[231] S. Priori,et al. Cardiac receptor activation and arrhythmogenesis. , 1993, European heart journal.
[232] F. Veglia,et al. Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels. , 1993, Atherosclerosis.
[233] R. Varco,et al. Women in the POSCH trial. Effects of aggressive cholesterol modification in women with coronary heart disease. The POSCH Group. Program on the Surgical Control of the Hyperlipidemias. , 1992, Annals of surgery.
[234] M. Sanmarco,et al. Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. , 1992, JAMA.
[235] D. Shapiro,et al. Long-term safety and efficacy profile of simvastatin. , 1991, The American journal of cardiology.
[236] R Peto,et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. , 1991, BMJ.
[237] C. Shear,et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. , 1991, The American journal of medicine.
[238] J. D. Proctor,et al. Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study , 1991, Clinical cardiology.
[239] J P Matts,et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.
[240] C. Shear,et al. Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia. , 1990, The American journal of cardiology.
[241] M. Beers,et al. The Merck Manual of Diagnosis and Therapy , 1982 .
[242] R. Nohara,et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[243] S. Ramsey,et al. An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes , 2012, PharmacoEconomics.
[244] F. Crea,et al. The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction? , 2011, Journal of cardiovascular medicine.
[245] M. Caulfield,et al. Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). , 2011, Ethnicity & disease.
[246] M. Shlipak,et al. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[248] C. Yuan,et al. Rationale and Design of the Carotid Plaque in Human for All Evaluations With Aggressive Rosuvastatin Therapy (CHALLENGER Trial) , 2009 .
[249] 治雄 中村. 1.MEGA Study(高脂血症に関する一次予防大規模試験) , 2009 .
[250] K. Watson. The JUPITER trial: How will it change clinical practice? , 2009, Reviews in cardiovascular medicine.
[251] R. Hubbard,et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. , 2009, British journal of clinical pharmacology.
[252] F. Ageev,et al. [Clinical and economical effectiveness of outpatient diagnostic coronary angiography]. , 2008, Kardiologiia.
[253] B. Golomb,et al. Statin Adverse Effects , 2008, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[254] H. Miyoshi,et al. Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[255] P. Miller,et al. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. , 2007, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.
[256] T. Gaziano. Reducing the growing burden of cardiovascular disease in the developing world. , 2007, Health affairs.
[257] P. Macfarlane,et al. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. , 2007, Journal of electrocardiology.
[258] Matthew A Silva,et al. Statin-related adverse events: a meta-analysis. , 2006, Clinical therapeutics.
[259] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[260] John Norrie,et al. Current Controlled Trials in Cardiovascular Medicine a Prospective Study of Pravastatin in the Elderly at Risk (prosper): Screening Experience and Baseline Characteristics , 2002 .
[261] M. Shinomiya,et al. Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) Study. , 2002, Journal of atherosclerosis and thrombosis.
[262] E. O’Brien. Anglo-Scandinavian cardiac outcomes trial : ASCOT : main protocol summary sub-study protocols , 2001 .
[263] T. Sheldon,et al. What role for statins? A review and economic model. , 1999, Health technology assessment.
[264] E. A. Nelson,et al. Systematic reviews of wound care management: (2). Dressings and topical agents used in the healing of chronic wounds. , 1999, Health technology assessment.
[265] S. Glasser,et al. The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg/dl. , 1996, The American journal of cardiology.
[266] M. Marmot,et al. Plasma cholesterol concentration and mortality. The Whitehall Study. , 1992, JAMA.
[267] C. Shear,et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. , 1991, Archives of internal medicine.